Introduction: Hematopoetic progenitor stem cells (HSCs, CD133+/CD45+) and very small embryonic-like stem cells (VSELs, CD133+/CD45−) can differentiate into specific immune cells. Some studies suggest that levels of HSCs and VSELs change during therapy with growth hormone (GH) or insulin-like growth factor 1 (IGF-1). GH deficiency (GHD), an endocrine disease connected with insufficient production of GH by pituitary gland, is treated with synthetic GH. IGF-1 is main growth factor, secreted under the influence of GH. Primary IGF-1 deficiency syndrome (PIGFDS) may be caused by genetic defects and it is treated with IGF-1.
Aim: The aim of the study was to estimate the concentration of very small embryonic-like cells (VSELs) delineated by Lin-CD133+CD45− phenotype and hematopoietic stem/progenitor cells characterized by Lin-CD133+CD45+ phenotype in relation to treatment with GH or IGF-1. To assess correlation between the level of HSCs and VSELs and anthropometric parameters.
Materials and methods: Anthropometric parameters (height, weight, BMI) and HSCs and VSELs levels were measured in 32 children with GHD during GH therapy and 4 with PIGFDS during IGF-1 therapy. Mean age 12 years old. The control group comprised 16 healthy, age and sex matched children. HSCs and VSELs levels were determined with flow cytometry.
Results: Comparing to control group HSCs level increases statistically significant (P<0,05) in the group treated with GH but tendency to increase without statistical significance was demonstrated by VSELs in both study groups and by HSCs in IGF-1 treated group. Statistically significant correlations (P<0,05) between stem cells levels and anthropometric parameters were observed in both GH (HSCs and weight, VSELs and height) and IGF-1 (VSELs and BMI, VSELs and height) treated patients.
Conclusion: In conclusion, GH and IGF-1 mobilize stem cells. VSELs and HSCs could be monitoring markers of patients response to therapy.
10 - 12 Sep 2016
European Society for Paediatric Endocrinology